PI3K inhibitor treatment of patients with ER+ breast cancer for ≥14 d induces upregulation of tumor ER levels and activity [43], which Toska et al. recently demonstrated is mediated by loss of AKT-induced epigenetic silencing of ER activity [44]. This evidence concerns the gene AKT1 and breast cancer.